Journal of Bioequivalence & Bioavailability

Derivative spectrophotometric method for the determination of Moxifloxacin in pharmaceutical formulations

3^rd World Congress Bioavailability & Bioequivalence

March 26-28, 2012 Marriott Hotel & Convention Centre, Hyderabad, India

V. Amrutha Sindhuja and M. Mathrusri Annapurna

Posters: J Bioequiv Availab

Abstract:

A simple precise and accurate derivative spectrophotometric method was developed for the determination of Moxifloxacin in pharmaceutical formulations in ortho phosphoric acid. Moxifloxacin is a synthetic broad spectrum antibacterial agent for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. It is a slightly yellow to yellow crystalline substance with a molecular weight of 437.9. Its empirical formula is C 21 H 24 FN 3 O 4 HCl. A double beam UV-VIS spectrophotometer (UV-1800, Shimadzu) connected to computer loaded with spectra manager software UV Probe was employed with spectral bandwidth of 1nm and wavelength accuracy of ? 0.3 nm with a pair of 10 mm matched quartz cells. Moxifloxacin has shown maxima at 283 nm and minima at 304 nm in first order derivative spectrum in ortho phosphoric acid and therefore the amplitude was chosen for the analytical calculations. A graph was drawn by taking concentration of the drug on the x- axis and the corresponding amplitude values on the y- axis. Moxifloxacin follows Beer- Lambert?s law over the concentration range of 0.2-30 μg/ml (r 2 = 0.999). The % RSD in precision and accuracy studies was found to be less than 2.0. The proposed methods were validated as per the ICH guidelines. The developed method can be successfully applied for the determination of Moxifloxacin in pharmaceutical formulations.